Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

3 1 1 1

What is this study about?

This clinical trial is focused on studying a condition known as congenital hemophilia A, a genetic disorder that affects the blood’s ability to clot properly, leading to excessive bleeding. The treatment being investigated is called emicizumab, which is a type of medication known as a humanized monoclonal antibody. Emicizumab is administered as a solution for injection under the skin, known as a subcutaneous injection. The study aims to determine if a personalized dosing approach, guided by the levels of the drug in the blood, is as effective as the standard dosing method in preventing bleeding episodes in patients with congenital hemophilia A.

Participants in the study will receive emicizumab, which is also known by its code names RO5534262 and ACE910. The study will compare two dosing strategies: the conventional dosing and a new approach that adjusts the dose based on how the drug is processed in the body, known as pharmacokinetic-guided dosing. The goal is to see if the personalized dosing can prevent treated bleeds, spontaneous joint or muscle bleeds, and overall bleeding as effectively as the conventional method.

The study will take place over several months, during which participants will be monitored for bleeding events and other health indicators. The trial will also assess the quality of life, joint health, and any pain experienced during the administration of emicizumab. By the end of the study, researchers hope to gather valuable information on the effectiveness and potential benefits of personalized dosing for individuals with congenital hemophilia A.

1 initial phase

Upon joining the study, the patient will continue their current treatment with emicizumab, a medication used to prevent bleeding in individuals with congenital haemophilia A.

The medication is administered as a subcutaneous injection, which means it is injected under the skin.

The dosage is 6 mg per kilogram of body weight every four weeks. This phase lasts for 12 months and is intended to ensure stability in bleeding control.

2 bleeding assessment phase

During this phase, the patient’s bleeding events are closely monitored over a period of 6 months.

The goal is to assess the frequency and severity of any bleeding episodes, including joint or muscle bleeds.

This information is crucial for evaluating the effectiveness of the current dosing regimen.

3 pharmacokinetic-guided dosing phase

In this phase, the dosing of emicizumab is adjusted based on pharmacokinetic data, which involves understanding how the drug is processed in the body.

The aim is to tailor the dosage to the individual needs of the patient, potentially improving the prevention of bleeding.

This phase also lasts for 6 months, during which the patient’s response to the adjusted dosing is evaluated.

4 dose continuation phase

Following the pharmacokinetic-guided dosing phase, the patient continues with the adjusted dosing regimen for an additional 6 months.

The focus remains on maintaining effective bleeding control and monitoring any changes in the patient’s condition.

Throughout this phase, regular assessments are conducted to ensure the treatment remains effective and safe.

5 final evaluation

At the end of the study, a comprehensive evaluation is conducted to compare the outcomes of the conventional dosing and the pharmacokinetic-guided dosing.

The primary measure is the proportion of patients without treated bleeds during the different phases.

Secondary measures include the frequency of spontaneous joint or muscle bleeds, the annualized bleeding rate, and the overall health-related quality of life.

Who Can Join the Study?

Have a confirmed diagnosis of congenital haemophilia A, which is a bleeding disorder present from birth, with a specific blood factor level (FVIII) of less than 6 IU/mL.
Be older than 1 year at the time of joining the study.
Have been receiving a specific treatment called emicizumab at a conventional dose for at least 12 months before joining the study.
Have good control over bleeding, meaning no unexpected joint or muscle bleeds in the last 6 months and no more than two treated bleeds due to injury in the last 6 months.
Be willing and able to provide written consent to participate, either by the patient or their parents/legal guardian.
Be willing to provide information about any bleeding episodes.
Be willing to follow the medication schedule as required by the study.

Who Cannot Join the Study?

Patients who do not have congenital haemophilia A. This is a condition where a person is born with a problem in their blood that makes it hard to stop bleeding.
Patients who are female, as the study is only for male participants.
Patients who are not within the specified age range for the study. The study is for certain age groups, so if you are too young or too old, you may not be able to participate.
Patients who belong to a vulnerable population. This means people who might need extra protection or care, like those with certain disabilities or conditions.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
University Hospital Maastricht	Maastricht	The Netherlands

Other Sites

Site Name	City	Country
Haga Hospital	Hague	The Netherlands
Universitair Medisch Centrum Utrecht	Utrecht	The Netherlands
Stichting Radboud University Medical Center	Nijmegen	The Netherlands
Ldgnx Ugrrungqrpnh Mmbaktp Cgvjqsv (sqhal	Leiden	The Netherlands
Uhfleprbkjfw Mocqzyp Carkwax Grhfcfdqv	Groningen	The Netherlands
Adajuomco Ull	Amsterdam	The Netherlands
Emijtcr Udlaqnsjavec Mttajxl Cnxhuol Rdjuwfowz (qjqnpvu Mty	Rotterdam	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Recruiting	25.06.2024

Trial locations

Investigated drugs:

Emicizumab

Emicizumab is a medication used in this study to help prevent bleeding in patients with congenital hemophilia A. It works by mimicking the action of a protein that helps blood to clot, which is missing or not working properly in people with this condition. The study is exploring whether adjusting the dose of Emicizumab based on how the body processes the drug (pharmacokinetic-guided dosing) is as effective as the standard dosing method in preventing bleeding episodes.

Congenital Hemophilia A – This is a genetic disorder characterized by a deficiency in clotting factor VIII, which is essential for blood clotting. Individuals with this condition experience prolonged bleeding or spontaneous bleeding episodes, particularly in joints and muscles. The severity of bleeding can vary, with some individuals experiencing frequent and severe bleeds, while others may have milder symptoms. Bleeding episodes can lead to joint damage over time if not managed properly. This condition is typically diagnosed in early childhood, often after a significant bleeding event. It is a lifelong condition that requires careful management to prevent bleeding complications.

Trial ID:

2024-515528-35-00

Protocol code:

22-571/21U-0151

NCT ID:

NCT06320626

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?